COPD

A study found that bronchodilator responsiveness more accurately forecasts FEV₁ decline and COPD development than polygenic risk scores.

The Q4 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

The pulmonology year in review highlights FDA approvals and pivotal data readouts.

The COPD year in review highlights FDA approvals, data, and advances in 2025.

2025 data show the US is still failing to adequately identify and initiate care for deadly lung disease. Experts discuss what it will take to turn the tide on this public health issue.

Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.

COPD management evolves with biologics, emphasizing personalized care and treatable traits to improve patient outcomes and address ongoing challenges.

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

Baseline emphysema detected in low-dose CT scans predicts long-term mortality in asymptomatic adults.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

Clinicians explore the evolving landscape of asthma and COPD treatment, emphasizing the role of biologics and biomarkers in personalized patient care.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.